Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


StemCells drops Batten, failing to find any patients

This article was originally published in Scrip

Executive Summary

Cell therapy specialist, StemCells Inc. is shelving a Phase Ib clinical trial in children with the rare genetic neurogenerative disorder neuronal ceroid lipofuscinosis (NCL), also known as Batten disease, having failed to identify any patients who fit the entry criteria. The trial design, which aimed to show that StemCells' purified human neural stem cells (HuCNS-SC) could be neuroprotective, called for pre-symptomatic patients, at a very early stage of the disease. However, early diagnosis is difficult, leaving the Palo Alto, California company wondering how to test the efficacy of its approach. The market wondered, too, with the company's shares down 8.7% on the news, closing at $0.79.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts